Within the scope of nmCRPC, several pivotal factors, including baseline PSA level, PSA velocity, and PSA doubling time, are intimately associated with vital patient outcomes including the time to initial bone metastasis, bone metastasis-free survival, and overall survival [2, 14]. This evidence concerns the gene KLK3 and bone metastasis.